COMPARISON BETWEEN SERUM LEVEL OF INTERLEUKIN-6 IN PSORIATIC PATIENTS BEFORE AND AFTER TREATMENT WITH METHOTREXATE AND ADALIMUMAB

Document Type : Preliminary preprint short reports of original research

Authors

1 Department of Dermatology, Venerology and Andrology

2 Department of Dermatology, Venereology and Andrology , Faculty of Medicine, Alexandria University, Egypt.

3 Department of Clinical and Chemical Pathology, Faculty of Medicine University of Alexandria.

4 Dermatology, Venereology and Andrology, Faculty of Medicine, Alexandria University.

Abstract

Psoriasis is a chronic illness with long coarse duration wich can affects all age groups and both sexes are equally affected, as other autoimmune disease it characterized by over production of many inflammatory cytokines including IL-6.
Clinically the disease characterized by well demarcated erythematous silvery plaques on affected areas. Psoriasis vulgaris is the most common type of psoriasis which account for 85-95% of all cases.
The disease has no permanent cure, but treatments lines were present to relief the symptoms of disease. There are several adopted modes of treatments available including, topical, UVR, systemic including oral and injectable treatments according to the disease severities.
Methotrexate and Adalimumab are most common systemic treatment in the management of plaque psoriasis with the good clinical response.
AIM OF WORK:
The aim of this study was to assess serum level of IL-6 before and after methotrexate treatment and compared to its level before and after treatment with adalimumab.

Keywords

ALEXMED ePosters
Volume 5, Issue 4
December 2023
Pages 36-37

Files

Share

How to cite

Statistics